Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs
Testosterone is the cornerstone therapy for men with hypogonadism, and also treats any associated anaemia by promoting erythropoiesis. However, excessive doses cause erythrocytosis (raised red cell mass), especially if other risk factors are present. Erythrocytosis is associated with arterial and ve...
Saved in:
| Main Authors: | Federica Tramontana, Azmi Mohammed, Yaasir H Mamoojee, Richard Quinton |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-06-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/14/6/EC-24-0695.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01) -
Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy
by: Maharan Kabha, et al.
Published: (2025-07-01) -
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study
by: Abdullahi Ahmed Mohamed, et al.
Published: (2025-08-01) -
The use of parenteral application of ferric carboxymaltose in the prevention of iron deficiency anaemia in suckling piglets
by: M Svoboda, et al.
Published: (2025-07-01) -
ERYTHROCYTOSIS IN CHILDREN: CASE REPORT
by: Teja Leban, et al.
Published: (2025-05-01)